Vaccinex, Inc. (VCNX)

5,94 -0,51 (-7,91%) Alla chiusura: 04:00PM EDT

Vaccinex, Inc.

1895 Mount Hope Avenue
Rochester, NY 14620
United States
585 271 2700
https://www.vaccinex.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 37

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Maurice Zauderer Ph.D.	Co-Founder, CEO, President & Director	411,7k	N/D	1947
Dr. Elizabeth E. Evans Ph.D.	COO and Senior VP of Discovery & Translational Medicine	291,57k	N/D	1973
Dr. Ernest S. Smith Ph.D.	Senior VP of Research & Chief Scientific Officer	297,25k	N/D	1972
Ms. Jill Sanchez CPA	Chief Financial Officer	N/D	N/D	1972
Dr. John E. Leonard Ph.D.	Senior Vice President of Development	N/D	N/D	1947

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.

Governance aziendale

L'ISS Governance QualityScore di Vaccinex, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.